Format

Send to

Choose Destination
See comment in PubMed Commons below
Gut. 2004 Jun;53(6):780-2.

Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease.

Author information

  • 1Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. sandborn.william@mayo.edu

Abstract

Patients with moderate to severely active Crohn's disease treated with infliximab may have a small but real risk of developing severe infections, opportunistic infections, and non-Hodgkin's lymphoma.

PMID:
15138201
PMCID:
PMC1774089
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center